Drug Profile


Alternative Names: (+)-(3aR)-phenserine; (+)-phenserine; Posiphen

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA); Raptor Pharmaceutical Corp
  • Developer Cenomed BioSciences; QR Pharma; Rockefeller University; University of California at Los Angeles
  • Class Nootropics; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Mild cognitive impairment; Parkinson's disease
  • Preclinical Brain injuries; Huntington's disease; Poisoning

Most Recent Events

  • 02 Mar 2017 Phase-I/II clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (PO) (NCT02925650)
  • 04 Oct 2016 QR Pharma and Alzheimer's Disease Cooperative Study plan the phase I/II DISCOVER trial for Alzheimer's disease in USA (PO, Capsule) (NCT02925650)
  • 24 Jun 2015 Phase-II development is ongoing for early Alzheimer's and Parkinson's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top